Landos Biopharma Reports Fourth Quarter and Full Year 2021
Continued Progress Towards Optimizing Clinical Development Plans On Track to Initiate Phase 2b Study of Omilancor in Ulcerative Colitis Later this Year ...
Source: globenewswire.com
Tim Mayleben News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Tim Mayleben. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Tim Mayleben Today - Breaking & Trending Today
Landos Biopharma Reports Fourth Quarter and Full Year 2021 Results and Provides Business Update
Continued Progress Towards Optimizing Clinical Development Plans On Track to Initiate Phase 2b Study of Omilancor in Ulcerative Colitis Later this Year Completed Enrollment of Phase 1b Trial of... | March 24, 2022
Source: marketscreener.com
Esperion Therapeutics CFO Richard Bartram to leave company | Crain's Detroit Business
Esperion Therapeutics Inc. is undergoing yet another change of leadership within its C-suite. The Ann Arbor-based pharmaceutical company disclosed on Tuesday that Richard Bartram, Esperion's CFO, was stepping down effective April 8, according to a filing with the U.S. Securities and Exchange…
Source: crainsdetroit.com
Esperion Therapeutics agrees to $18.25M settlement in class action case
The plaintiffs in a 5-year-old lawsuit alleging securities fraud against an Ann Arbor drugmaker could get a settlement later this summer. The class action lawsuit, filed in May 2016, alleges that Esperion Therapeutics Inc. and its CEO Tim Mayleben, made false and misleading statements to…
Source: crainsdetroit.com
Esperion Therapeutics agrees to $18.25 million settlement in class action lawsuot
The plaintiffs in a 5-year-old lawsuit alleging securities fraud against an Ann Arbor drugmaker could get a settlement later this summer. The class action lawsuit, filed in May 2016, alleges that Esperion Therapeutics Inc. and its CEO Tim Mayleben, made false and misleading statements to…
Source: crainsdetroit.com